[Antineoplastic drug-induced extravasation].
Klinik für Innere Medizin - Hämatologie und Onkologie, Vivante Klinikum Neukölln, Berlin, Germany. maike.dewitt@vivantes.de
Maike
M
de Wit
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003680:Deglutition Disorders / Q000188:drug therapy / Q000532:radiotherapy; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine; D014945:Wound Healing / Q000187:drug effects
D014747:Vinblastine; D006821:Hyaluronoglucosaminidase; D002945:Cisplatin; D000077235:Vinorelbine